Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
data for the 400 mg cohort — to assess time- and dose-dependency ; earlier single-dose 240 mg data showed about nearly 10% visceral fat reduction, sustained lean mass, and a ~0.9% placebo-adjusted body-weight change at three months. WVE-007 (GalNAc-siRNA targeting Inhibin ßE/Activin E) is being positioned to improve body composition—“ become leaner, not lighter ”—by reducing visceral fat while preserving muscle, with a Phase 2a planned in higher-BMI/comorbid patients that will include MRI liver-fat imaging to explore hepatic fat/MASH opportunities and support once- to twice-yearly dosing claims. Wave's RNA editing program in AATD is due multi-dose 400 mg Q4W data and mid-year regulatory discussions, with the company pursuing a biomarker strategy that could enable an accelerated approval pathway aimed at shifting patients toward a heterozygous-like protective protein response. Interested in WAVE Life Sciences Ltd.? Here are five stocks we like better. Golden Cross Alert: 3 Stoc
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International ConferenceGlobeNewswire
- WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Wave Life Sciences Ltd. (WVE): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings [Yahoo! Finance]Yahoo! Finance
WVE
Earnings
- 2/26/26 - Miss
WVE
Sec Filings
- 2/27/26 - Form 4
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- WVE's page on the SEC website